Phio Pharmaceuticals (NASDAQ:PHIO) Earns “Buy” Rating from HC Wainwright

Phio Pharmaceuticals (NASDAQ:PHIO)‘s stock had its “buy” rating restated by HC Wainwright in a research note issued on Tuesday,Benzinga reports. They currently have a $14.00 price objective on the stock.

Several other research firms have also recently weighed in on PHIO. Wall Street Zen cut Phio Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, November 1st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Phio Pharmaceuticals in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $14.00.

Phio Pharmaceuticals Stock Up 15.2%

Phio Pharmaceuticals stock opened at $1.29 on Tuesday. The company has a 50 day moving average of $1.09 and a 200-day moving average of $1.68. Phio Pharmaceuticals has a twelve month low of $0.81 and a twelve month high of $4.19. The stock has a market capitalization of $13.88 million, a PE ratio of -0.60 and a beta of 0.94.

Phio Pharmaceuticals (NASDAQ:PHIO) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.44) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.01. Equities analysts anticipate that Phio Pharmaceuticals will post -8.54 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Phio Pharmaceuticals stock. Geode Capital Management LLC raised its stake in Phio Pharmaceuticals Corp. (NASDAQ:PHIO) by 38.7% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 57,694 shares of the company’s stock after purchasing an additional 16,108 shares during the quarter. Geode Capital Management LLC owned approximately 1.20% of Phio Pharmaceuticals worth $136,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 57.31% of the company’s stock.

Phio Pharmaceuticals Company Profile

Phio Pharmaceuticals, Inc (NASDAQ: PHIO) is a clinical‐stage biotechnology company focused on the discovery and development of dual RNA interference (RNAi) therapeutics. Utilizing its proprietary Transitional RNAi (TRiMTM) platform, Phio aims to simultaneously silence multiple gene targets to achieve enhanced therapeutic activity. The company’s core mission is to advance next‐generation RNAi compounds with potential applications in oncology and immuno‐oncology.

Phio’s TRiMTM platform is designed around the delivery of synthetic, double‐stranded RNA duplexes that can be engineered to target specific combinations of genes implicated in tumor growth and immune evasion.